Dying young
Eliminating racial disparities in neuromuscular disease outcomes
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Decades of research show that racial and ethnic minority patients have worse access to health care and inferior clinical outcomes than white patients.1,2 Life expectancy for all racial groups continues to improve in the United States, yet remains about 5 years less for black than white patients, primarily because of black patients' higher rate of heart disease.3 The racial disparity is not limited to cardiac conditions—the same inequity exists for neurologic conditions. Black patients die younger than white patients from cerebrovascular disease; have less access to Parkinson disease treatments, such as dopaminergic medications or deep brain stimulation; are less likely to receive acute interventions like tissue plasminogen activator for ischemic stroke; and are referred less often for subspecialty evaluations.4–8 Black–white disparities are now evident for patients with muscular dystrophy (MD), a group of inherited muscle diseases that lead to early death due to respiratory or cardiac failure.
In this issue of Neurology®, Kenneson et al.9 deepen our view of racial inequities in neurologic care and outcomes by reporting strikingly early mortality for black patients with MD. The authors examined 20 years of US mortality data and found that black patients …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosisLilyana Amezcua, Jessica B. Smith, Edlin G. Gonzales et al.Neurology, March 09, 2020 -
Views & Reviews
Reducing neurodisparityRecommendations of the 2017 AAN Diversity Leadership ProgramErika T. Marulanda-Londoño, Michelle W. Bell, Omotola A. Hope et al.Neurology, January 18, 2019 -
Articles
Lower use of carotid artery imaging at minority-serving hospitalsEric M. Cheng, Salomeh Keyhani, Susan Ofner et al.Neurology, June 13, 2012 -
Article
Race/ethnicity influences outcomes in young adults with supratentorial intracerebral hemorrhageLaura C. Miyares, Guido J. Falcone, Audrey Leasure et al.Neurology, January 22, 2020